zidesamtinib   Click here for help

GtoPdb Ligand ID: 12392

Synonyms: Example 5 [US383715659] | Jideytro® | NVL-520 | NVL520
Approved drug PDB Ligand
zidesamtinib is an approved drug
Compound class: Synthetic organic
Comment: This is the chemical structure for the INN zidesamtinib (a tyrosine kinase inhibitor that is intended as an antineoplastic agent). Zidesamtinib's structure matches that for the brain penetrant ROS1 inhibitor NVL-520, that was designed to overcome ROS1G2032R-mediated resistance to lorlatinib, entrectinib and crizotinib [1,4]. Objective tumour responses were observed in 3 patients with ROS1 mutation-positive lung cancers (including with brain metastases) that were resistant to other tyrosine kinase inhibitor therapies [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 91.17
Molecular weight 419.46
XLogP 2.19
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCN1C2=C(CC3=NN(C)N=C3C4=CC=C(C=C4[C@@H](C)OC5=CC2=CN=C5N)F)C=N1
Isomeric SMILES CCN1N=CC2=C1C3=CC(O[C@H](C)C4=CC(F)=CC=C4C5=NN(C)N=C5C2)=C(N)N=C3
InChI InChI=1S/C22H22FN7O/c1-4-30-21-13(11-26-30)7-18-20(28-29(3)27-18)16-6-5-15(23)9-17(16)12(2)31-19-8-14(21)10-25-22(19)24/h5-6,8-12H,4,7H2,1-3H3,(H2,24,25)/t12-/m1/s1
InChI Key DTWUUAFTYSMNQX-GFCCVEGCSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Nuvalent progressed NVL-520 to clinical evaluation, in patients with advanced/metastatic tumours with constitutively active (mutated) ROS1 tyrosine kinase. The US FDA approved zidesamtinib in July 2026 [3], to treat advanced/metastatic ROS1-positive non-small cell lung cancer in patients who have already been treated with a ROS1 inhibitor (e.g., lorlatinib, entrectinib, crizotinib).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05118789 A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) Phase 1/Phase 2 Interventional Nuvalent Inc. The first-in-human ARROS-1 study
NCT06797362 Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors Expanded Access Nuvalent Inc.